Status:
COMPLETED
Electronic Transmission of Laboratory and Adherence Records of Heart Failure Patients to General Practitioners Screen
Lead Sponsor:
University Hospital, Basel, Switzerland
Conditions:
Heart Failure
Eligibility:
All Genders
Brief Summary
Patients with heart failure (HF) need multiple guideline-directed medications to control the systolic and/or diastolic ventricular dysfunction. Laboratory measure the biomarker NT-proBNP (N-terminal p...
Detailed Description
Patients with heart failure (HF) need multiple guideline-directed medications to control the systolic and/or diastolic ventricular dysfunction. To support clinical decision and to guide treatment at e...
Eligibility Criteria
Inclusion
- is ≥ 18 years old;
- was diagnosed with HF NYHA II-III;
- is under multiple regimen (ACE-Inhibitors and/or mineralocorticoid receptor antagonist (MRA) and/or betablocker (BB) and/or diuretic and/or other);
- did not reach targeted clinical and/or biomedical objectives (HF is inadequately controlled);
- self-administers medication (no help or supervision from a third person);
- is suspected of inappropriate intake behaviour;
- accepts to use the monitoring device for one month;
- accepts a home-visit from the study pharmacist one month later;
- signs the informed consent form.
Exclusion
- \- Patients who are, in the opinion of the physician, unlikely to comply with the study schedule or are unsuitable for any other reason
Key Trial Info
Start Date :
August 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 27 2021
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT04326101
Start Date
August 15 2020
End Date
September 27 2021
Last Update
November 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Praxis Hammer
Basel, Switzerland, 4057